ArticlePLoS pathogens2022
An introduction to the Marburg virus vaccine consortium, MARVAC.
Open access · goldAbstract read
In one paragraph
Article in PLoS pathogens, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 34 papers.
0numbers the graph read from it
0cells of the map it votes in
34citing papers in PubMed
6.2field-weighted citation impact, top 2% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
34 citing papers in PubMed, 50 citations in OpenAlex.
- Vaccine preparedness for Bundibugyo virus and lessons learned.NPJ vaccines · 2026Article
- Marburg Virus Glycoprotein Is a Remarkable Virulent Factor Linked to Hemorrhagic Pathology: Evidence from Multimodal Experimental Systems.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Article
- Revisiting Ravn virus as the lesser known orthomarburgvirus.Npj viruses · 2026Review
- Rational design of next-generation filovirus vaccines combining glycoprotein stabilization and nanoparticle display with glycan modification.Nature communications · 2025Article
- Rational design of next-generation filovirus vaccines through glycoprotein stabilization, nanoparticle display, and glycan modification.bioRxiv : the preprint server for biology · 2025Article
- The immunomodulatory p43 secreted protein of Trichuris whipworm parasites is a lipid carrier that binds signalling lipids and precursors.Scientific reports · 2025Article
- Marburg Virus Disease: A Narrative Review.Health science reports · 2025Article
- Oral obeldesivir provides postexposure protection against Marburg virus in nonhuman primates.Nature medicine · 2025Article
- Advancements and Challenges in Addressing Zoonotic Viral Infections with Epidemic and Pandemic Threats.Viruses · 2025Review
- Evaluation of Vaccines and Therapeutics Against Marburg Virus in Nonhuman Primate Models.Methods in molecular biology (Clifton, N.J.) · 2025Article
- Review
- Cryo-EM structure of single-layered nucleoprotein-RNA complex from Marburg virus.Nature communications · 2024Article
- Filovirus vaccines as a response paradigm for emerging infectious diseases.NPJ vaccines · 2024Review
- The cellular protein phosphatase 2A is a crucial host factor for Marburg virus transcription.Journal of virology · 2024Article
- Marburg virus exploits the Rab11-mediated endocytic pathway in viral-particle production.Microbiology spectrum · 2024Article
- Prevalence of human filovirus infections in sub-Saharan Africa: A systematic review and meta-analysis protocol.Systematic reviews · 2024Article
- Review
- Design of a novel multi-epitope vaccine against Marburg virus using immunoinformatics studies.BMC biotechnology · 2024Article
- The urgency of Marburg therapeutics: preventing local outbreaks from the potential global spread.Frontiers in microbiology · 2024Article
- The Current Pathogenicity and Potential Risk Evaluation of Marburg Virus to Cause Mysterious "Disease X"-An Update on Recent Evidences.Environmental health insights · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
45 authors at 20 institutions in 7 countries.
Robert W CrossGalveston National Laboratory, and Department of Microbiology and Immunology, University of Texas Medical Branch, Galveston, Texas, United States of America.
Ira M LonginiDepartment of Biostatistics, University of Florida, Gainesville, Florida, United States of America.
Stephan BeckerInstitute for Virology, Philipps-Universität Marburg, Marburg, Germany.
Karin BokVaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland, United States of America.
David BoucherU.S. COVID-19 Response at U.S. Department of Health and Human Services, Washington, DC, United States of America.
Miles W CarrollPandemic Sciences Institute, Nuffield Department of Medicine, Oxford University, United Kingdom.
Janet V DíazWorld Health Organization, Geneva, Switzerland.
William E DowlingCoalition for Epidemic Preparedness Innovations (CEPI), Washington, Washington, DC, United States of America.
Ruxandra Draghia-AkliJohnson & Johnson-Global Public Health Research and Development, Spring House, Pennsylvania, United States of America.
James T DuworkoPartnership for Research on Infectious Diseases in Liberia, Monrovia, Liberia.
John M DyeVirology Division, United States Army Medical Research Institute of Infectious Diseases, Frederick, Maryland, United States of America.
Michael A EganAuro Vaccines, Pearl River, New York, United States of America.
Patricia FastIAVI, New York, New York, United States of America.
Amy FinanSabin vaccine Institute, Washington, DC, United States of America.
Courtney FinchSabin vaccine Institute, Washington, DC, United States of America.
Thomas R FlemingUniversity of Washington, Seattle, Washington, United States of America.
Joan FuscoPublic Health Vaccines, Cambridge, Massachusetts, United States of America.
Thomas W GeisbertGalveston National Laboratory, and Department of Microbiology and Immunology, University of Texas Medical Branch, Galveston, Texas, United States of America.
Anthony GriffithsNational Emerging Infectious Diseases Laboratories, Boston University School of Medicine, Boston, Maryland, United States of America.
Stephan GüntherBernhard Nocht Institute for Tropical Medicine, Hamburg, Germany.
Lisa E HensleyIntegrated Research Facility, Division of Clinical Research, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Frederick, Maryland, United States of America.
Anna HonkoNational Emerging Infectious Diseases Laboratories, Boston University School of Medicine, Boston, Maryland, United States of America.
Ruth HunegnawImmune Biology of Retroviral Infection Section, Vaccine Branch, National Cancer Institute, National Institutes of Health, Bethesda, Maryland, United States of America.
Jocelyn JakubikSabin vaccine Institute, Washington, DC, United States of America.
Julie LedgerwoodVaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland, United States of America.
Kerstin LuhnJanssen Vaccines & Prevention, Leiden, the Netherlands.
Demetrius MatassovAuro Vaccines, Pearl River, New York, United States of America.
Jeffrey MeshulamAuro Vaccines, Pearl River, New York, United States of America.
Emily V NelsonBernhard Nocht Institute for Tropical Medicine, Hamburg, Germany.
Christopher L ParksIAVI, New York, New York, United States of America.
Roxana RustomjeeSabin vaccine Institute, Washington, DC, United States of America.
David SafronetzZoonotic Diseases and Special Pathogens Division, National Microbiology Laboratory, Public Health Agency of Canada, Winnipeg, Manitoba, Canada.
Lauren M SchwartzWorld Health Organization, Geneva, Switzerland.
Dean SmithBacterial and Combination Vaccines, Public Health Agency of Canada, Ottawa, Ontario, Canada.
Paul SmockSabin vaccine Institute, Washington, DC, United States of America.
Ydrissa SowCollaborative Clinical Research Branch, Division of Clinical Research, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Rockville, Maryland, United States of America.
Christina F SpiropoulouViral Special Pathogens Branch, Division of High-Consequence Pathogens and Pathology, National Center for Emerging and Zoonotic Infectious Diseases, Centers for Disease Control and Prevention, Atlanta, Georgia, United States of America.
Nancy J SullivanVaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland, United States of America.
Kelly L WarfieldEmergent BioSolutions, Gaithersburg, Maryland, United States of America.
Daniel WolfeBacterial and Combination Vaccines, Public Health Agency of Canada, Ottawa, Ontario, Canada.
Courtney WoolseyGalveston National Laboratory, and Department of Microbiology and Immunology, University of Texas Medical Branch, Galveston, Texas, United States of America.
Roland ZahnJanssen Vaccines & Prevention, Leiden, the Netherlands.
Ana María Henao-RestrepoWorld Health Organization, Geneva, Switzerland.
César Muñoz-FontelaBernhard Nocht Institute for Tropical Medicine, Hamburg, Germany.
Andrea MarziLaboratory of Virology, Division of Intramural Research, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Hamilton, Montana, United States of America.ORCID 0000-0003-0186-9587
National Institutes of Health · USSabin Vaccine Institute · USBernhard Nocht Institute for Tropical Medicine · DEPublic Health Agency of Canada · CAThe University of Texas Medical Branch at Galveston · USWorld Health Organization · CHBoston University · USInternational AIDS Vaccine Initiative · USJanssen (Netherlands) · NLCenters for Disease Control and Prevention · USCoalition for Epidemic Preparedness Innovations · USEmergent BioSolutions (United States) · USJohnson & Johnson (United States) · USLiberian Institute for Biomedical Research · LRPhilipps University of Marburg · DEUnited States Army Medical Research Institute of Infectious Diseases · USUnited States Department of Health and Human Services · USUniversity of Florida · USUniversity of Oxford · GBUniversity of Washington · US
Funding
SDMC: HPTN 084 Pregnancy SupplementUM1AI068617 · NIAID · FRED HUTCHINSON CANCER RESEARCH CENTER · PI Elizabeth Renata Brown, Deborah J Donnell · 2011 to 2026
$204.9MResearch Project 3: siRNA Therapy and Small Molecule Combination Treatment for FilovirusesU19AI142785 · NIAID · UNIVERSITY OF TEXAS MED BR GALVESTON · PI GEISBERT, THOMAS WILLIAM · 2019 to 2023
$35.5MWest African Center for Emerging Infectious DiseasesU01AI151801 · NIAID · UNIVERSITY OF TEXAS MED BR GALVESTON · PI Robert W Cross, Scott C Weaver · 2020 to 2026
$10.1MSTATISTICAL ISSUES IN AIDS RESEARCHR37AI029168 · NIAID · UNIVERSITY OF WASHINGTON · PI JAMES P HUGHES · 1999 to 2026
$9.8MDesign and Analysis of Vaccine Trials for Emerging Infectious Disease ThreatsR01AI139761 · NIAID · UNIVERSITY OF FLORIDA · PI DEAN, NATALIE EXNER · 2018 to 2022
$3.6MMathematical and Statistical Methods for the Control of Global Infectious Disease ThreatsR56AI148284 · NIAID · UNIVERSITY OF FLORIDA · PI HALLORAN, M ELIZABETH, LONGINI, IRA M · 2020 to 2020
$802kNIAID NIH HHS HHSN272200800056CNIAID NIH HHS R01 AI139761NIAID NIH HHS R37 AI029168NIAID NIH HHS R56 AI148284NIAID NIH HHS U01 AI151801NIAID NIH HHS U19 AI142785NIAID NIH HHS UM1 AI068617World Health Organization 001
Abstract
The emergence of Marburg virus (MARV) in Guinea and Ghana triggered the assembly of the MARV vaccine "MARVAC" consortium representing leaders in the field of vaccine research and development aiming to facilitate a rapid response to this infectious disease threat. Here, we discuss current progress, challenges, and future directions for MARV vaccines.
Indexed as
MarburgvirusMarburg Virus DiseaseViral VaccinesAnimalsHumansViral Vaccines
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC0
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.